PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical

PCI Pharma Services Provide Updates on Manufacturing Facility at BIO

PCI Pharma Services will use the BIO International Convention, 16-19th June in Boston, as a platform to introduce its new purpose-built facility for large-scale sterile fill-finish operations at its campus in nearby Bedford, NH.

PCI experts will provide attendees with key updates as the 50,000-square-foot facility approaches full-scale GMP production this summer.   

With site construction and infrastructure installation now complete, PCI has commenced qualification activities for the Bedford plant’s Annex 1-compliant sterile fill-finish manufacturing technologies. Among other highlights, the facility houses an aseptic vial fill-finish line within a fully isolated containment system, equipped with twin 430-sq-ft lyophilisers featuring automatic loading and unloading systems. Providing additional capacity to accommodate PCI’s recent and anticipated growth, the robust, high-speed integrated filler can produce batches of up to 300,000 vials at speeds up to 400 per minute. 

The site constitutes the third high-throughput, isolator-based commercial sterile fill-finish facility that PCI has built in the last four years. As it comes online, the new facility further improves PCI’s capacity and capabilities for the sterile fill-finish of late-phase clinical and large-scale commercial small molecule and biologic drugs – including life-changing, high-value drug products such as mAbs, fusion proteins and peptides.  

PCI also is expanding its pharmaceutical development capabilities at its Bedford campus. The initiative’s highlights include repurposing an existing building into a dedicated Development Center of Excellence (CoE) providing formulation, analytical and process development, as well as stability testing.  

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026